Showing 4381-4390 of 6947 results for "".
- Merck, Moderna Initiate Phase 3 Study of V940-KEYTRUDA Combo for Adjuvant Treatment of Resected High-risk Melanomahttps://practicaldermatology.com/news/merck-moderna-initiate-phase-3-study-of-v940-mrna-4157-in-combination-with-keytruda-for-adjuvant-treatment-of-patients-with-resected-high-risk-melanoma/2461890/Merck today announced th
- WCD News: Connect Biopharma's Rademikibart Earns High Marks in ADhttps://practicaldermatology.com/news/wcd-news-connect-biopharmas-rademikibart-earns-high-marks-in-ad/2461851/Four new studies support the efficacy and safety of rademikibart in atopic dermatitis (AD), Connect Biopharma reports. Rademikibart (CBP-201), a next-generation IL-4Rα antibody, achieved all primary and secondary endpoints in a randomized pivotal trial for moderate-to-severe
- Biosimilar Update: Fresenius Kabi’s Idacio Joins Growing List of Available Humira Biosimilarshttps://practicaldermatology.com/news/biosimilar-update-fresenius-kabis-idacio-joins-growing-list-of-available-humira-biosimilars/2461836/Fresenius Kabi’s citrate-free adalimumab biosimilar
- EAACI News: Barzolvolimab May Help Tame Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/eaaci-news-barzolvolimab-may-help-tame-chronic-spontaneous-urticaria/2461786/Celldex Therapeutics, Inc.’s barzolvolimab is looking good in chronic spontaneous urticaria, according to data from the Phase 1b single-dose cholinergic cohort included in the chronic inducible urticaria (CIndU) trial that was presented at the European Academy of Allergy and Clini
- Study Uncovers How B Cells React to Melanomahttps://practicaldermatology.com/news/study-uncovers-how-b-cells-react-to-melanoma/2461773/Antibody-producing B cells may be defective in responding to melanoma, a new study suggests. The study is published in Nature Communications. Researchers used advanced technologies to delve into the antibody immune response in blood and tissues of patients with m
- HEROES Educational Campaign Highlights Role of Salons in Promoting Skin and Scalp Healthhttps://practicaldermatology.com/news/heroes-educational-campaign-highlights-role-of-salons-in-promoting-skin-and-scalp-health/2461766/The Globa
- EULAR News: Amgen's Otzela Cools Inflammation, May Improve CV Health in PsAhttps://practicaldermatology.com/news/eular-news-amgens-otzela-cools-inflammation-may-improve-cv-health-in-psa/2461749/Otezla (apremilast) showed promising results in cooling inflammation and reducing cardiometabolic risk factors in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), in Milan, Italy. The MOSAIC Phase
- AOBiome’s B244 Eases Eczema Symptoms, Helps Tame Itchhttps://practicaldermatology.com/news/aobiomes-b244-eases-eczema-symptoms-helps-tame-itch/2461723/AOBiome Therapeutics, Inc.’s B244 treatment demonstrated significant improvements in eczema severity and itch reduction The Phase 2b clinical data is published in
- DermaSensor’s Skin Cancer Device May Help Primary Care Providers Spot Skin Cancerhttps://practicaldermatology.com/news/dermasensors-skin-cancer-device-may-help-internists-spot-skin-cancer/2461703/DermaSensor Inc.’s nove
- AI Model Helps AD Patients Diagnose Complications, Cancerhttps://practicaldermatology.com/news/ai-model-helps-ad-patients-diagnose-complications-cancer/2461606/A new artificial intelligence (AI) model can empower atopic dermatitis (AD) patients to detect complications from bacterial or viral infections and distinguish between eczema and skin lesions caused by mycosis fungoides. The AI model is detailed in a paper published in the